Centogene N.V. (CNTG) has released an update.
CENTOGENE N.V. and Evotec SE have discovered a promising new molecule that could potentially treat neuronopathic Gaucher disease. The two companies have extended their partnership, with Evotec leading the next phase of pre-clinical research and holding an exclusive option to acquire CENTOGENE’s share of the IP. If exercised, this could result in license fees, milestone payments, and royalties for CENTOGENE, although financial specifics remain undisclosed.
For further insights into CNTG stock, check out TipRanks’ Stock Analysis page.
